These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 32053311)
21. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS; Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946 [TBL] [Abstract][Full Text] [Related]
22. [Treatment of Cystic Fibrosis with CFTR Modulators]. Tümmler B Pneumologie; 2016 May; 70(5):301-13. PubMed ID: 26894479 [TBL] [Abstract][Full Text] [Related]
23. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis. Yeh JT; Yu YC; Hwang TC J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177 [TBL] [Abstract][Full Text] [Related]
34. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator. Yu YC; Sohma Y; Hwang TC J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474 [TBL] [Abstract][Full Text] [Related]
35. The march towards CFTR modulator access for all people with CF: The end of the beginning. VanDevanter DR J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080 [No Abstract] [Full Text] [Related]
36. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351 [TBL] [Abstract][Full Text] [Related]
37. Triple CFTR Modulator Therapy for Cystic Fibrosis. Holguin F N Engl J Med; 2018 Oct; 379(17):1671-1672. PubMed ID: 30334694 [No Abstract] [Full Text] [Related]
38. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700 [TBL] [Abstract][Full Text] [Related]
39. Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination. Pócsi M; Fejes Z; Bene Z; Nagy A; Balogh I; Amaral MD; Macek M; Nagy B J Cyst Fibros; 2023 Nov; 22(6):1085-1092. PubMed ID: 37087300 [TBL] [Abstract][Full Text] [Related]
40. Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A. Bratcher PE; Hunt KC; Pickard K; Taylor-Cousar JL J Cyst Fibros; 2019 Mar; 18(2):e9-e10. PubMed ID: 30348612 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]